Floatz logo

Talzenna

Recurrent Malignant Solid Neoplasm

St. Jude Children's Research HospitalPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
81/ 100

Competitive context

75 Active assets in the Recurrent Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Crizotinib
M.D. Anderson Cancer Center
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Epirubicin
University of California, Davis
Phase 2B
Cyclophosphamide
Anusha Kalbasi
Phase 2B

View all 50 →

Same molecule, other indications

Talzenna is also rated in:

BRCA2-related cancer predispositionDormant
BB
Indicative ·
68 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →